<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273802</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-CPX-MDS</org_study_id>
    <nct_id>NCT04273802</nct_id>
  </id_info>
  <brief_title>CPX-351 in Higher Risk Myelodysplastic Syndromes</brief_title>
  <official_title>CPX-351 in Higher Risk Myelodysplastic Syndromes: a Phase I/ II Study as First Line or After Hypomethylating-agents Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic
      syndromes : as first line treatment or after hypomethylating agents failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I/II study of the efficacy of CPX-351 treatment in patients with higher risk
      myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure.

      CPX-351 is an advanced liposomal formulation of daunorubicin and cytarabine encapsulated at a
      1:5 ratio.

      Patients will receive induction treatment with CPX-351. Patients in response (complete
      response (CR), complete response with incomplete hematologic improvement (CRi), partial
      response (PR)) after induction will receive monthly courses of consolidation therapy with
      CPX-351.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort A: first line treatment Cohort B: after hypomethylating-agents failure</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (CR, CRi, PR)</measure>
    <time_frame>28 to 42 days after induction</time_frame>
    <description>Response to induction therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (CR, CRi, PR, HI)</measure>
    <time_frame>28 to 42 days after induction</time_frame>
    <description>Response to induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>42 months</time_frame>
    <description>Event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>42 months</time_frame>
    <description>Duration of the response to induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>42 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile - Duration of cytopenias</measure>
    <time_frame>42 months</time_frame>
    <description>Duration of cytopenias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile - life threatening or fatal cytopenias</measure>
    <time_frame>42 months</time_frame>
    <description>Number of life threatening or fatal cytopenias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile - hospitalization</measure>
    <time_frame>42 months</time_frame>
    <description>Time spent in hospital for induction and consolidation cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of minimal residual disease (MRD) after induction and after the last consolidation</measure>
    <time_frame>42 months</time_frame>
    <description>Evaluation of MRD by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of minimal residual disease (MRD) after induction and after the last consolidation</measure>
    <time_frame>42 months</time_frame>
    <description>Evaluation of variant allelic frequency (VAF) of Baseline mutations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble Fms-like tyrosine kinase 3 ligand concentration (sFLc) in plasma during induction</measure>
    <time_frame>42 months</time_frame>
    <description>sFLc plasma level assessments at day 1 of induction just before starting treatment, and then at days 8, 15 and 22 of induction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Cohort A - First line treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Untreated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - Hypomethylating failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in absence of response after hypomethylating agents treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351 in cohort A</intervention_name>
    <description>Treatment by CPX-351 via intravenous infusion over 90 minutes.
Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.
If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.
If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1.</description>
    <arm_group_label>Cohort A - First line treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351 in cohort B</intervention_name>
    <description>Treatment by CPX-351 via intravenous infusion over 90 minutes.
This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.
In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1.</description>
    <arm_group_label>Cohort B - Hypomethylating failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myelodysplastic syndrome (WHO 2016 classified) including CMML (even if white blood
             cell count (WBC) &gt; 13000/mm3).

          -  For COHORT A: untreated patients except by erythropoiesis stimulating agents,
             Lenalidomide or non-chemotherapy during a phase of lower risk MDS; For COHORT B:
             absence of response (CR, CRi, PR or HI according to international working group (IWG)
             2006 for MDS) after a minimum of 6 cycles of single hypomethylating agent or relapse
             after a response.

          -  For COHORT A: less than 20% of marrow blasts. For COHORT B: less than doubling of
             marrow blasts compared with onset of hypomethylating agent.

          -  Classical international prognostic scoring system (IPSS) int-2 or high risk score.

          -  For COHORT A: age between 18 and 70 years; For COHORT B: age ≥ 18 years.

          -  For COHORT A: Performance status (ECOG grading) ≤ 1; For COHORT B: Performance status
             ≤ 2.

          -  Eligible for standard intensive chemotherapy.

          -  Absence of concomitant severe cardiovascular disease which would make intensive
             chemotherapy impossible, i.e. arrhythmias requiring chronic treatment, congestive
             heart failure or symptomatic ischemic heart disease, reduced left ventricular function
             assessed by multigated acquisition (MUGA) scan or echocardiogram.

          -  Patient must have adequate organ function as indicated by the following laboratory
             values: Renal: Serum creatinine &lt; 2 mg/dl or calculated creatinine clearance ≥ 60
             mL/min by MDRD (modification of the diet in renal disease) or CKD-EPI (chronic kidney
             disease epidemiology collaboration) equation for patients with creatinine levels &gt;
             1.5xULN ; Hepatic: Serum total bilirubin ≤ 2.5xULN OR direct bilirubin ≤ ULN for
             patients with total bilirubin levels ≥ 2 mg/dL, aspartate aminotransferase (ALT) and
             alanine aminotransferase (ALT) ≤ 2.5xULN, Alkaline Phosphatase ≤ 5xULN (if &gt; 2.5xULN,
             then liver fraction should be ≤ 2.5xULN).

          -  Patients not known to be refractory to platelet transfusions.

          -  Female subjects of child-bearing potential must agree to undergo medically supervised
             pregnancy test prior to starting study drug. The first pregnancy test will be
             performed at screening (within 7 days prior to first study drug administration), and
             on the day of the first study drug administration and confirmed negative prior to
             dosing and Day 1 before dosing all subsequent cycles. Female patient is not actively
             breastfeeding at the time of study entry.

          -  Female patients are either post-menopausal, free from menses for &gt; 2 years, surgically
             sterilized or willing to use 2 adequate barrier methods of contraception to prevent
             pregnancy or agree to abstain from becoming pregnant throughout the study, starting
             with Visit 1. Females of reproductive potential as well as fertile men and their
             partners who are female of reproductive potential must agree to abstain from sexual
             intercourse or to use two highly effective forms of contraception from the time of
             giving informed consent, during the study and for 6 months (females and males)
             following the last dose of CPX-351.

          -  Male patients agree to use an adequate method of contraception for the duration of the
             study. Men should be advised not to father a child while receiving CPX-351 and for 6
             months post study.

          -  Patients are available for regular blood sampling, study related assessments, and
             appropriate clinical management at the treating institution for the duration of the
             study.

          -  Patients have the ability to understand and willingness to sign an informed consent
             form indicating the investigational nature of the study.

        Exclusion Criteria:

          -  Active and uncontrolled infection.

          -  Last dose of hypomethylating agent given more than 4 months before entering the trial.

          -  Uncontrolled intercurrent illness or circumstances that could limit compliance with
             the study, including but not limited to the following: symptomatic congestive heart
             failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or
             psychiatric or social conditions that may interfere with patient compliance.

          -  Current participation or participation in a study with an investigational compound or
             device within 30 days of initial dosing with study drug.

          -  Known human immunodeficiency virus (HIV) infection or HIV-related malignancy.

          -  Clinically active hepatitis B or hepatitis C infection.

          -  Known allergy or hypersensitivity to any component of CPX-351.

          -  &quot;Currently active&quot; second malignancy, other than non-melanoma skin cancer and in situ
             carcinoma of the cervix.

          -  Subjects with a history of Wilson's disease or other copper-related disorder.

          -  Treatment with growth factors such as erythropoietin alfa (EPO) or granulocyte
             colony-stimulating factor (G-CSF) or cytotoxic and non-cytotoxic agents (including low
             dose oral chemotherapy with the exception of hydroxyurea) in the 30 days before
             inclusion.

          -  Treatment with systemic steroids that has not been stabilized to the equivalent of ≤
             10 mg/day prednisone during the 4 weeks prior to the start of the study drugs.

          -  Clinical evidence of central nervous system leukemia.

          -  Pregnancy or breastfeeding during the projected duration of the study.

          -  Absence of social security.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre PETERLIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre PETERLIN, MD</last_name>
    <phone>+33 2 40 08 74 18</phone>
    <email>pierre.peterlin@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatiha CHERMAT</last_name>
    <phone>+33 1 71 20 70 59</phone>
    <email>fatiha.chermat-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens - Service d'hématologie clinique et thérapie cellulaire</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bérengère GRUSON, MD</last_name>
      <phone>+33 3 22 45 59 14</phone>
      <email>gruson.berengere@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bérengère GRUSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine CHARBONNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magalie JORIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers - Service des maladies du sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain THEPOT, MD</last_name>
      <phone>+33 2 41 35 44 66</phone>
      <email>sylvain.thepot@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain THEPOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corentin ORVAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline SCHMIDT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz - Service d'hématologie clinique</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana BERCEANU, MD</last_name>
      <phone>+33 3 81 66 83 51</phone>
      <email>aberceanu@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Ana BERCEANU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne DAGUINDAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yohan DESBROSSES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Clinique universitaire d'hématologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie PARK, MD</last_name>
      <phone>+33 4 76 76 62 77</phone>
      <email>spark@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie PARK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne THIEBAUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric GARBAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans - Service d'onco-hématologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamel LARIBI, MD</last_name>
      <phone>+33 2 43 43 43 61</phone>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel LARIBI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie DENIZON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne BESANCON-BERGELIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges - Hôpital Dupuytren - Service d'hématologie clinique et thérapie cellulaire</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal TURLURE, MD</last_name>
      <phone>+33 5 55 05 66 42</phone>
      <email>pascal.turlure@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal TURLURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed TOUATI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane MOREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu - Service d'Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre PETERLIN, MD</last_name>
      <phone>+33 2 40 08 32 71</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre PETERLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice CHEVALLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry GUILLAUME, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU-Hôpital Archet I - Service d'Hématologie Clinique</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas CLUZEAU, MD</last_name>
      <phone>+33 4 92 03 58 44</phone>
      <email>cluzeau.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas CLUZEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel LOSCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Michel KARSENTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Service Hématologie Séniors</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre FENAUX, MD</last_name>
      <phone>+33 1 71 20 70 22</phone>
      <email>pierre.fenaux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FENAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie SEBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel ADES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital de Haut-Lévêque - Service des maladies du sang</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie DIMICOLI-SALAZAR, MD</last_name>
      <phone>+33 5 57 65 65 11</phone>
      <email>sophie.dimicoli-salazar@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie DIMICOLI-SALAZAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud PIGNEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axelle LASCAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Service d'onco-hématologie et thérapie cellulaire</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Miguel TORREGROSA DIAZ, MD</last_name>
      <phone>+33 5 48 44 44 44</phone>
      <phone_ext>45415</phone_ext>
      <email>jose-miguel.torregrosa-diaz@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jose Miguel TORREGROSA DIAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie CAYSSIALS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Pilar GALLEGO HERNANZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT-oncopole - Fédération Hématologie - Médecine Interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile BEYNE-RAUZY, MD</last_name>
      <phone>+33 5 31 15 62 64</phone>
      <email>beynerauzy.odile@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Odile BEYNE-RAUZY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibault COMONT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne TAVITIAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS high risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

